Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05852171
Other study ID # ZYYY-IGM-001
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 1, 2023
Est. completion date October 31, 2025

Study information

Verified date April 2023
Source First Affiliated Hospital of Zhejiang University
Contact Zefeng Xuan, Doctor
Phone 18100189899
Email xuanzefeng@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will explore the mechanism of targeted drug in treatment of idiopathic granulomatous mastitis, and clarify the clinical classification and corresponding markers.


Description:

This study is aim to explore the mechanism of baricitinib in regulating the occurrence and development of idiopathic granulomatous mastitis, as well as the clinical classification and potential markers of idiopathic granulomatous mastitis. The target population of interest in this study is patients with non-lactating mastitis, which requires core needle biopsy pathology to indicate mastitis or biopsy pathology of palpable mass indicates chronic interstitial cell infiltration. Measurable lesions are required. The primary end point was the clinical complete remission rate, and the secondary end point was the degree of focus reduction, the recurrence rate within 12 months after drug withdrawal, the degree of inflammation markers decline, and the toxicity and side effects of the drug.


Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Baricitinib
Baricitinib administered orally

Locations

Country Name City State
China The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
First Affiliated Hospital of Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Complete Remission Rate(CRR) CRR defined as the proportion of patients who have a confirmed Complete Remission (CR) , as determined by the investigator at local site per RECIST 1.1.In this study, CR is defined as the complete healing of the lesion and the return of inflammation index to normal level indicated by special physical examination and breast ultrasound. Until progression or recurrence, assessed up to approximately 24 months
Secondary The change of lesion diameter The change of lesion diameter is measured by special physical examination and breast ultrasound. Until progression, assessed up to approximately 24 months
Secondary Recurrence rate within 12 months after drug withdrawal Percentage of patients who recur within 12 months after drug withdrawal. Until progression or recurrence, assessed up to approximately 12 months after drug withdrawal
Secondary Degree of inflammation markers change Determination the concentration of inflammation markers, such as TNF-a, IL-6, IL-17a and CRP, in serum at different time points after baricitinib administered orally. Until progression, assessed up to approximately 24 months
Secondary Toxicity and side effects of the drug Occurrence of adverse events (AEs) after baricitinib administered orally according to NCI CTCAE v5.0. Up to follow-up period, approximately 24 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04424615 - Idiopathic Granulomatous Mastitis
Active, not recruiting NCT04096300 - An Integrative Approach for Idiopathic Granulomatous Mastitis.
Completed NCT05409586 - Risk Factors and the Role of Albumin-to-globulin Ratio in Idiopathic Granulomatous Mastitis
Recruiting NCT05361629 - Idiopathic Granulomatous Mastitis Combination Therapy N/A